Literature DB >> 16601839

High urokinase expression contributes to the angiogenic properties of endothelial cells derived from circulating progenitors.

Agnès Basire1, Florence Sabatier, Sophie Ravet, Edouard Lamy, Agnès Mialhe, Gwladys Zabouo, Pascale Paul, Victor Gurewich, José Sampol, Françoise Dignat-George.   

Abstract

Endothelial progenitor cells (EPC) display a unique ability to repair vascular injury and promote neovascularization although the underlying molecular mechanisms remain poorly understood. Urokinase-type plasminogen activator (uPA) and its receptor (uPAR) play a critical role in cell migration and angiogenesis by facilitating proteolysis of extracellular matrix. The aim of the present study was to characterize the uPA/uPAR-dependent proteolytic potential of EPC outgrown from human umbilical cord blood and to analyze its contribution to their angiogenic properties in vitro. Cells derived from EPC (EPDC), presenting typical features of late outgrowth endothelial cells, were compared to mature endothelial cells, represented by human umbilical vein endothelial cells (HUVEC). Using quantitative flow cytometry, enzyme-linked immunosorbent assays and zymography, we demonstrated that EPDC displayed higher levels of uPA and uPAR. In conditioned culture media, uPA-dependent proteolytic activity was also found to be significantly increased in EPDC. This activity was paralleled by a higher secretion of pro-metalloproteinase-2 (pro-MMP-2). Inhibition of EPDC-associated uPA by monoclonal antibodies that block either uPA activity or receptor binding, significantly reduced proliferation, migration and capillary like tube formation. Moreover, tumor necrosis factor-alpha and vascular endothelial growth factor, known to be locally secreted in ischemic areas, further increased the proteolytic potential of EPDC by up-regulating uPA and uPAR expression respectively. The EPDC response to these factors was found to be more pronounced than that of HUVEC. In conclusion, these findings indicated that EPDC are characterized by high intrinsic uPA/uPAR-dependent proteolytic potential that could contribute to their invasive and angiogenic behaviour.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16601839

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  19 in total

Review 1.  Nanotechnology in cell replacement therapies for type 1 diabetes.

Authors:  Alexander U Ernst; Daniel T Bowers; Long-Hai Wang; Kaavian Shariati; Mitchell D Plesser; Natalie K Brown; Tigran Mehrabyan; Minglin Ma
Journal:  Adv Drug Deliv Rev       Date:  2019-02-02       Impact factor: 15.470

Review 2.  Targeting stem cell niches and trafficking for cardiovascular therapy.

Authors:  Nicolle Kränkel; Gaia Spinetti; Silvia Amadesi; Paolo Madeddu
Journal:  Pharmacol Ther       Date:  2010-10-20       Impact factor: 12.310

3.  Tumoral and choroidal vascularization: differential cellular mechanisms involving plasminogen activator inhibitor type I.

Authors:  Maud Jost; Catherine Maillard; Julie Lecomte; Vincent Lambert; Marc Tjwa; Pierre Blaise; Maria-Luz Alvarez Gonzalez; Khalid Bajou; Silvia Blacher; Patrick Motte; Chantal Humblet; Marie Paule Defresne; Marc Thiry; Francis Frankenne; André Gothot; Peter Carmeliet; Jean-Marie Rakic; Jean-Michel Foidart; Agnès Noël
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

4.  Cleaved high molecular weight kininogen inhibits tube formation of endothelial progenitor cells via suppression of matrix metalloproteinase 2.

Authors:  Y Wu; J Dai; N G Schmuckler; N Bakdash; M C Yoder; C M Overall; R W Colman
Journal:  J Thromb Haemost       Date:  2009-10-23       Impact factor: 5.824

5.  Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover.

Authors:  Zhong Dong; Allen D Saliganan; Hong Meng; Sanaa M Nabha; Aaron L Sabbota; Shijie Sheng; R Daniel Bonfil; Michael L Cher
Journal:  Neoplasia       Date:  2008-05       Impact factor: 5.715

6.  A systematic approach to the establishment and characterization of endothelial progenitor cells for gene therapy.

Authors:  Natalie Jayne Werling; Robin Thorpe; Yuan Zhao
Journal:  Hum Gene Ther Methods       Date:  2013-04-30       Impact factor: 2.396

7.  Activation of plasminogen into plasmin at the surface of endothelial microparticles: a mechanism that modulates angiogenic properties of endothelial progenitor cells in vitro.

Authors:  Romaric Lacroix; Florence Sabatier; Agnès Mialhe; Agnès Basire; Ralph Pannell; Hélène Borghi; Stephane Robert; Edouard Lamy; Laurent Plawinski; Laurence Camoin-Jau; Victor Gurewich; Eduardo Angles-Cano; Françoise Dignat-George
Journal:  Blood       Date:  2007-07-02       Impact factor: 22.113

8.  Endothelial progenitor cells and integrins: adhesive needs.

Authors:  Francisco Caiado; Sérgio Dias
Journal:  Fibrogenesis Tissue Repair       Date:  2012-03-12

9.  Long-Term Expansion in Platelet Lysate Increases Growth of Peripheral Blood-Derived Endothelial-Colony Forming Cells and Their Growth Factor-Induced Sprouting Capacity.

Authors:  Dimitar Tasev; Michiel H van Wijhe; Ester M Weijers; Victor W M van Hinsbergh; Pieter Koolwijk
Journal:  PLoS One       Date:  2015-06-15       Impact factor: 3.240

10.  Increased VEGFR2 expression during human late endothelial progenitor cells expansion enhances in vitro angiogenesis with up-regulation of integrin alpha(6).

Authors:  David M Smadja; Ivan Bièche; Dominique Helley; Ingrid Laurendeau; Ghislaine Simonin; Laurent Muller; Martine Aiach; Pascale Gaussem
Journal:  J Cell Mol Med       Date:  2007 Sep-Oct       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.